Last updated: July 26, 2026
R-Tech Ueno, Ltd. v. Apotex, Inc. 1:15-cv-00592: Litigation Summary, Claims at Stake, and Likely Patent-Exclusivity Impact
R-Tech Ueno, Ltd. v. Apotex, Inc., No. 1:15-cv-00592, is a US Hatch-Waxman patent-infringement action tied to Apotex’s proposed generic product submission against an R-Tech Ueno reference drug. The case procedurally tracks the standard Paragraph IV playbook: infringement allegations, claim construction and dispositive motions, and a resolution that typically determines whether Apotex can launch at risk or is delayed by an injunction. This matter’s business impact is primarily launch-timing and licensing leverage, not trial merits, unless a final judgment resolves inventorship/validity or narrows the asserted claims materially.
Outcome-specific details (asserted patents, claim map themes, court rulings, settlement/injunction terms, and final judgment dates) are not provided in the record available here, so a complete, accurate litigation analysis cannot be produced.
What patents were asserted in R-Tech Ueno, Ltd. v. Apotex, Inc. 1:15-cv-00592?
Answer: Not specified in the information provided.
Which R-Tech Ueno patents typically drive Paragraph IV disputes?
For R-Tech Ueno’s portfolio, disputes in this category usually center on one or more of the following patent families:
- composition of matter patents (active ingredient and key polymorph/solvate forms)
- formulation patents (vehicle, ratios, stabilizers, release modifiers)
- method-of-use patents (dosing regimens, patient subgroups, therapeutic method claims)
- manufacturing method patents (sterilization, granulation, crystallization, drying parameters)
What to extract from the docket to identify the asserted estate
A litigation summary should cite:
- the asserted patent numbers listed in the complaint and amended pleadings
- the factual basis for infringement (ANDA labels, samples, or proposed manufacturing process)
- the declaratory-judgment counterclaims (non-infringement, invalidity)
None of those case-specific particulars are available in the supplied inputs.
When did R-Tech Ueno sue Apotex in 1:15-cv-00592, and what was the filing posture?
Answer: Not specified in the information provided.
What the timeline should contain for a Hatch-Waxman case
A full timeline normally includes:
- complaint filing date and venue
- service and answer dates
- motions to dismiss or to stay
- claim construction scheduling
- pretrial and trial dates (if any)
- final judgment or dismissal date
No docket milestones are available here.
How strong is the patent estate for R-Tech Ueno in 1:15-cv-00592 based on litigation posture?
Answer: Not specified in the information provided.
What “strength” means in this context
Patent strength is usually inferred from:
- how many claims survive dispositive motions
- claim construction outcomes (especially for means-plus-function or functional limitations)
- validity outcomes (anticipation, obviousness, written description, enablement)
- whether the case settles early (often a sign of value leakage concerns) or proceeds to Markman and summary judgment (often a sign that key limitations are disputed)
No rulings are provided here, so no reliability-graded strength analysis can be issued.
What did claim construction decide in R-Tech Ueno v. Apotex (1:15-cv-00592)?
Answer: Not specified in the information provided.
Claim construction topics that usually determine infringement
In ANDA cases, courts often construe:
- particle size distribution, crystallinity, polymorph identifiers
- dissolution profile targets and test methods
- method steps tied to objective parameters
- ranges (for example temperature, pH, excipient levels) that map to the ANDA process
Without the Markman order and construed terms, a claims-to-infringement bridge cannot be produced accurately.
Did the court enter a preliminary injunction or grant a permanent injunction?
Answer: Not specified in the information provided.
What injunctions would signal commercially
- Preliminary injunction: launch delay risk increases sharply.
- No injunction, dismissal on merits: generic launch could proceed depending on other barriers.
- Partial injunction tied to specific claims: design-around strategy becomes the focus.
No injunction record is included.
How did Paragraph IV arguments play out in R-Tech Ueno v. Apotex?
Answer: Not specified in the information provided.
Standard Paragraph IV argument structure
Plaintiffs typically argue:
- statutory infringement based on the ANDA’s label and proposed manufacturing
- invalidity defenses: non-obviousness, adequate written description, valid priority claims
Defendants typically argue:
- non-infringement due to differences in formulation, process, or use instructions
- invalidity via prior art and lack of enablement or indefiniteness
No briefing outcomes are available.
What was the resolution: settlement, dismissal, or final judgment in 1:15-cv-00592?
Answer: Not specified in the information provided.
What to record for an enforceable business conclusion
A litigation summary that supports licensing or investment decisions should include:
- settlement agreement date
- whether there was a covenant-not-to-sue or a consent judgment
- launch timing or “skinny label” restrictions
- any stipulated damages or confidentiality-related terms that affect valuation models
- dismissal with or without prejudice
No resolution terms are included.
What FDA and Orange Book events correspond to 1:15-cv-00592?
Answer: Not specified in the information provided.
Why FDA events matter for litigation-to-commercial translation
For Hatch-Waxman cases, the litigation drives and is driven by:
- ANDA submission dates and Paragraph IV certifications
- Orange Book patent listings and periods of exclusivity
- FDA approval dates that follow a settlement or court ruling
Absent the reference product and the Orange Book patent identifiers, the FDA linkage cannot be stated.
How many patents and which jurisdictions were affected by R-Tech Ueno v. Apotex?
Answer: Not specified in the information provided.
US-only vs. multi-forum impacts
A single district-court case typically affects:
- the US launch channel for the ANDA product
- the specific asserted Orange Book-listed patents
Multi-forum effects would include:
- related cases in other districts
- ITC actions
- license enforcement in parallel state or federal cases
No scope is provided.
Which generic launch scenarios were at risk because of 1:15-cv-00592?
Answer: Not specified in the information provided.
Common launch scenarios shaped by litigation outcomes
Depending on the resolution:
- full launch at risk (if no injunction and validity survives)
- delayed launch until patent expiry
- launch with carve-outs (label changes) if only method-of-use claims are constrained
- design-around formulation (if formulation claims are narrowed)
Without the asserted patent types and outcome, no scenario mapping can be performed reliably.
Key litigation data table for 1:15-cv-00592 (required fields)
| Field |
Value |
| Case caption |
R-Tech Ueno, Ltd. v. Apotex, Inc. |
| Docket number |
1:15-cv-00592 |
| Court / division |
Not provided |
| Complaint filing date |
Not provided |
| Asserted patent numbers |
Not provided |
| ANDA / FDA reference product |
Not provided |
| Claim construction date and order |
Not provided |
| Summary judgment / JMOL motions |
Not provided |
| Injunction ruling |
Not provided |
| Settlement / dismissal / final judgment |
Not provided |
Key Takeaways
- No case-specific litigation facts (asserted patents, claim construction, dispositive outcomes, settlement terms, or injunction status) are provided in the available inputs, so an accurate litigation summary and analysis cannot be produced.
- A complete business analysis for 1:15-cv-00592 requires the asserted-patent list, the procedural milestones, and the resolution date and form (settlement vs. judgment). Those elements are not present here.
- Any attempt to infer asserted patents or outcome from the docket number alone would not meet accuracy requirements for high-stakes R&D, licensing, or litigation planning.
FAQs
What does “1:15-cv-00592” indicate in Hatch-Waxman litigation?
It indicates a federal civil case filed in 2015 with docket number 1:15-cv-00592, but it does not identify the asserted patents or resolution.
What is usually included in the complaint in Paragraph IV cases like this?
Usually infringement allegations tied to specific Orange Book-listed patents and a description of how the proposed ANDA product infringes.
How do claim construction outcomes affect generic launch timing?
Constructions narrow or broaden the claim limitations, which can drive summary judgment on infringement and influence settlement value.
Does a settlement always block generic entry until patent expiry?
Not always; settlements can include launch dates, design-around carve-outs, or covenants-not-to-sue that allow earlier entry.
How can litigation outcome affect Orange Book patent strategy?
It can change which patents are leveraged for exclusivity blocking, which are safe to license, and which are candidates for design-around R&D.
References
(Empty because no sources were provided in the input.)
